BioMarin to Participate in Two Upcoming Investor Conferences
BioMarin Pharmaceutical (BMRN) announced participation in two major investor conferences in November 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BioMarin Pharmaceutical (BMRN) announced participation in two major investor conferences in November 2022. The Credit Suisse 31st Annual Healthcare Conference is scheduled for November 8 at 8:35 am PT in Rancho Palos Verdes, CA. The 13th Annual Jefferies Global Healthcare Conference will take place on November 16 at 8:35 am GMT in London, England. Live webcasts will be available on the company's investor website, with archived presentations accessible afterward.
Details
News Market Reaction – BMRN
The recorded move for BMRN in the trading session of this news was +0.84%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Credit Suisse 31st Annual Healthcare Conference 2022: November 8th, 8:35amPT/11:35amET, in Rancho Palos Verdes, CA
- 13th Annual Jefferies Global Healthcare Conference 2022: November 16th, 8:35amGMT, in London, England
SAN RAFAEL, Calif., Nov. 3, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at two upcoming investor conferences. To access the live webcasts, please visit: https://investors.biomarin.com/. An archived version of the presentations will also be available through the Company's website for a limited time following the conference.
About BioMarin
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare disorders. The company's portfolio consists of seven commercialized products and multiple clinical and pre-clinical product candidates.
For additional information, please visit www.biomarin.com. Information on BioMarin's website is not incorporated by reference into this press release.
Contacts: | |
Investors | Media |
Traci McCarty | Debra Charlesworth |
BioMarin Pharmaceutical Inc. | BioMarin Pharmaceutical Inc. |
(415) 455-7558 | 415) 455-7451 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/biomarin-to-participate-in-two-upcoming-investor-conferences-301667428.html
SOURCE BioMarin Pharmaceutical Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.